Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
June 12 2023 - 8:45AM
Business Wire
Omeros Corporation (Nasdaq: OMER) today announced that the
slides presented yesterday in the “late-breaker” session at the
2023 European Hematology Association (EHA) Congress in Frankfurt,
Germany are now available on Omeros’ website. The presentation,
which details data from a pre-specified interim analysis from the
ongoing Phase 1b clinical trial of Omeros’ lead MASP-3 inhibitor
OMS906 in complement-inhibitor-naïve adults with paroxysmal
nocturnal hemoglobinuria (PNH), was identified by EHA’s Scientific
Program Committee as one of the top five late-breaking submissions
and selected for oral presentation. The presentation, entitled
OMS906, A mannan-binding lectin-associated serine protease-3
(MASP-3) Inhibitor, Normalizes Hemoglobin Levels in Treatment-naïve
PNH Patients: Interim Data from a Proof-of-Concept Clinical Trial,
was delivered to a large audience by Jens Panse, MD, Senior
Physician and Deputy Director of the Department of Hematology,
Oncology, Hemostaseology and Stem Cell Transplantation, University
Hospital RWTH Aachen, and Managing Medical Director of the Center
for Integrated Oncology, Aachen, Germany.
Also available on Omeros’ website is a second presentation at
EHA – Alternative Pathway MASP-3 Inhibitor OMS906: Results from a
First-in-Man Phase 1 Study in Healthy Subjects and Study Design of
Two Ongoing Clinical Trials in Patients with PNH – by Morag
Griffin, MBChB, FRCPath, Consultant in Haematology of St. James
University Teaching Hospital, Leeds, United Kingdom. This poster
presentation describes findings from a single-ascending dose study
evaluating OMS906 safety, pharmacokinetics and pharmacodynamics in
healthy subjects.
About PNH
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare,
life-threatening acquired disorder that causes production of red
blood cells lacking certain surface proteins (CD55 and CD59),
making them vulnerable to destruction by the complement system.
This leads to intravascular hemolysis (destruction of red blood
cells within blood vessels) and extravascular hemolysis (when
damaged red blood cells are removed by macrophages in the spleen or
liver). Left untreated, PNH is associated with debilitating anemia,
a high risk of thrombosis, fatigue, and a severely reduced survival
rate. There remains a significant unmet need for PNH therapies, as
a large proportion of patients treated with C5 inhibitors continue
to experience hemolysis and approximately one third of them still
require red blood cell transfusions.
About OMS906
OMS906 is an investigational human monoclonal antibody targeting
mannan-binding lectin-associated serine protease-3 (MASP-3), the
key activator of the complement system’s alternative pathway. The
complement system plays a central role in inflammation and becomes
activated as a result of tissue damage or microbial infection.
Responsible for the conversion of pro-complement factor D to
complement factor D, MASP-3 is believed to be the premier target in
the alternative pathway. MASP-3 has the lowest native circulating
level and low relative clearance compared to the other alternative
pathway proteins and, unlike C5 and C3 blockers, MASP-3 inhibition
leaves intact the lytic arm of the classical pathway, important for
fighting infection. Also, unlike other components of the
alternative pathway, MASP-3 is believed not to be an acute phase
reactant, which could provide a significant advantage to MASP-3
inhibitors, like OMS906, over other alternative pathway inhibitors.
MASP-3 inhibitors are thought to have preventive or therapeutic
effects across a broad range of diseases including PNH, hemolytic
uremic syndrome (HUS), atypical HUS, traumatic brain injury,
arthritis, wet age-related macular degeneration,
ischemia-reperfusion injury, transplant-related complications and
other immune-related disorders. Through its growing and exclusive
intellectual property position, Omeros controls the use of MASP-3
inhibitors across a wide range of alternative pathway-related and
other diseases and disorders.
About Omeros Corporation
Omeros is an innovative biopharmaceutical company committed to
discovering, developing and commercializing small-molecule and
protein therapeutics for large-market and orphan indications
targeting immunologic disorders including complement-mediated
diseases, cancers, and addictive and compulsive disorders. Omeros’
lead MASP-2 inhibitor narsoplimab targets the lectin pathway of
complement and is the subject of a biologics license application
pending before FDA for the treatment of hematopoietic stem cell
transplant-associated thrombotic microangiopathy (TA-TMA).
Narsoplimab is also in multiple late-stage clinical development
programs focused on other complement-mediated disorders, including
IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome.
Omeros’ long-acting MASP-2 inhibitor OMS1029 is currently in a
Phase 1 clinical trial. OMS906, Omeros’ inhibitor of MASP-3, the
key activator of the alternative pathway of complement, is
advancing across multiple clinical programs for alternative
pathway-related diseases, including paroxysmal nocturnal
hemoglobinuria (PNH) and complement 3 (C3) glomerulopathy. For more
information about Omeros and its programs, visit
www.omeros.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230612185884/en/
Jennifer Cook Williams Cook Williams Communications, Inc.
Investor and Media Relations ir@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2024 to May 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From May 2023 to May 2024